In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.
19 February 2014 | Eurekalert Medicine & Health
On January 17, 2014, FDA approved changes to the Victrelis (boceprevir) package insert to expand the list of contraindicated medications and update the Drug Interaction section.
23 January 2014 | FDA
Every 10 years of age independently raised chances that a person in a US HIV cohort would be prescribed an antiretroviral and a nonantiretroviral that should not be given together. One third of cohort members were prescribed medications with moderate or high evidence of a possible drug-drug interaction.
26 November 2013 | International AIDS Society
The poster presentation A Single Dose Food Effect Study of Raltegravir Formulations (Poster #PE10/17) will be presented Thursday, Oct. 17, and Friday, Oct. 18, from 12:00 p.m. to 2:00 p.m. CET. Based on the results of this study and other data, Merck plans to initiate a Phase III clinical study on a once daily dosing regimen of ISENTRESS in early 2014, pending review by regulatory agencies. ISENTRESS is administered twice daily, in accordance with the approved Prescribing Information.
16 October 2013 | Merck press release
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Tybost(TM) (cobicistat 150 mg tablets), a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection.
26 September 2013 | Gilead press release
Study in mice shows verapamil enhances isoniazid plus rifampin antibiotic therapy.
02 September 2013 | Johns Hopkins Medicine press release
When researchers say they are trying to do more with less in the fight against HIV, they mean it. At last month's International AIDS Society (IAS) conference in Kuala Lumpur, Malaysia, researchers presented preliminary results from a clinical trial that showed a lower dose of the commonly used antiretroviral drug efavirenz was just as effective as the approved higher dose and seemed to cause fewer side effects in study participants.
07 August 2013 | Nature Medicine
Researchers have had early success in a method that might one day thwart the powerful blood-brain barrier and effectively deliver antiretrovirals to the brain.
16 May 2013 | AIDSMeds
Ritonavir, darunavir/ritonavir, and atazanavir/ritonavir all more than tripled exposure of cenicriviroc, an investigational CCR5 and CCR2 receptor antagonist, in 60 healthy volunteers. There were no serious or unexpected adverse events in these 20-day studies.
14 May 2013 | NATAP
FDA recently approved changes to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes: Lists Stribild as one of the drugs that should not be coadministered with Atripla; Adds drug interaction information for raltegravir, boceprevir and telaprevir.
18 April 2013 | FDA